HomeCompareCTCXW vs ORCC

CTCXW vs ORCC: Dividend Comparison 2026

CTCXW yields 7490.64% · ORCC yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTCXW wins by $3219325239215192.50M in total portfolio value
10 years
CTCXW
CTCXW
● Live price
7490.64%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3219325239215192.50M
Annual income
$3,136,944,464,329,217,000,000.00
Full CTCXW calculator →
ORCC
ORCC
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full ORCC calculator →

Portfolio growth — CTCXW vs ORCC

📍 CTCXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTCXWORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTCXW + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTCXW pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTCXW
Annual income on $10K today (after 15% tax)
$636,704.12/yr
After 10yr DRIP, annual income (after tax)
$2,666,402,794,679,834,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, CTCXW beats the other by $2,666,402,794,679,834,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTCXW + ORCC for your $10,000?

CTCXW: 50%ORCC: 50%
100% ORCC50/50100% CTCXW
Portfolio after 10yr
$1609662619607596.25M
Annual income
$1,568,472,232,164,608,400,000.00/yr
Blended yield
97.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

CTCXW
No analyst data
Altman Z
-38.0
Piotroski
4/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
-68.0% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTCXW buys
0
ORCC buys
0
No recent congressional trades found for CTCXW or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTCXWORCC
Forward yield7490.64%4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR0%5%
Portfolio after 10y$3219325239215192.50M$28.0K
Annual income after 10y$3,136,944,464,329,217,000,000.00$899.19
Total dividends collected$3213812604182292.00M$6.4K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CTCXW vs ORCC ($10,000, DRIP)

YearCTCXW PortfolioCTCXW Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$759,764$749,063.67$11,120$420.00+$748.6KCTCXW
2$54,000,925$53,187,977.91$12,357$458.31+$53.99MCTCXW
3$3,590,852,097$3,533,071,107.68$13,721$499.76+$3590.84MCTCXW
4$223,408,125,107$219,565,913,362.68$15,227$544.58+$223408.11MCTCXW
5$13,005,862,347,544$12,766,815,653,679.31$16,885$593.02+$13005862.33MCTCXW
6$708,523,022,229,903$694,606,749,518,031.20$18,713$645.34+$708523022.21MCTCXW
7$36,122,824,222,390,480$35,364,704,588,604,476.00$20,724$701.81+$36122824222.37MCTCXW
8$1,723,706,063,164,109,000$1,685,054,641,246,151,400.00$22,938$762.73+$1723706063164.09MCTCXW
9$76,991,378,398,107,710,000$75,147,012,910,522,120,000.00$25,372$828.41+$76991378398107.69MCTCXW
10$3,219,325,239,215,192,500,000$3,136,944,464,329,217,000,000.00$28,047$899.19+$3219325239215192.50MCTCXW

CTCXW vs ORCC: Complete Analysis 2026

CTCXWStock

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Full CTCXW Calculator →

ORCCBDC

ORCC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in ORCC shares.

Full ORCC Calculator →
📬

Get this CTCXW vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTCXW vs SCHDCTCXW vs JEPICTCXW vs OCTCXW vs KOCTCXW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.